"We expect the Company's current strong performance to continue into 2009 and are confident that the product portfolio will continue to deliver exceptional results. In addition, we are investing heavily in our pipeline to further drive future performance and deliver long term growth."
Notes to Editors:
About The Binding Site
The Binding Site Ltd. is a British based company specialising in the research, development and production of immunodiagnostic kits and reagents. The Binding Site manufactures a wide range of high quality and innovative products used in clinical laboratories world-wide. The business is divided into three main areas:-
Freelite(TM), a novel and highly significant assay increasingly used
for the diagnosis and monitoring of multiple myeloma (MM), a cancer of
cells in the bone marrow. MM is the second most common blood cancer after
non-Hodgkin's lymphoma. Considered almost untreatable only 20 years ago,
huge strides have been made in the successful treatment of multiple myeloma
with new drugs becoming available and new treatment regimes being assessed.
Freelite has been used as a sensitive marker for the efficacy of some of
these newer treatments and has helped clinicians gain a clear understanding
of how some of these drugs are benefiting their patients. Furthermore, with
numerous different therapies now available, treatment decisions which may
have taken weeks or months can now be made in days thanks to the
availability of sensitive and reliable results using Freelite. National and
International guidelines for the diagnosis and treatment of multiple
myeloma and associated cancers now include Freelite results as a
requirement for monitoring the treatment of patients. Numerous clinical
trials are underway to look at the use of Fr
|SOURCE The Binding Site Limited|
Copyright©2008 PR Newswire.
All rights reserved